TYRA — Tyra Biosciences Inc
NASDAQ · Healthcare · Biotechnology
$25.47
+$0.17 (+0.67%)
Tyra Biosciences Inc (TYRA) is a biotechnology company listed on NASDAQ. It is led by Todd Harris Ph.D., based in 2656 State Street, Carlsbad, CA, United States, 92008, with about 60 employees. Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Net income was -$29.9M. TYRA currently screens at market cap $531.8M.
Use this TYRA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TYRA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TYRA SEC filings page. Lician reads the product cache first so this HTML stays unique to Tyra Biosciences Inc even when a live quote feed is slow.
About Tyra Biosciences Inc
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
TYRA Key Statistics
Market Cap
$531.78M
Volume
314,403
Previous Close
$26.09
Day Range
$26.30 – $26.99
EPS
-$1.51
Revenue
$0.00
Net Income
-$86.48M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
60
TYRA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$86.48M | -$69.13M | -$55.33M | -$26.29M |
| EPS (Diluted) | -$1.51 | -$1.62 | -$1.32 | -$1.91 |
Total Assets
$363.56M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$91.97M
Operating Cash Flow
-$69.77M
Free Cash Flow
$0.00
Tyra Biosciences Inc Company Information
- Co-Founder, President, CEO, Secretary, Treasurer & Director
- Todd Harris Ph.D.
- Headquarters
- 2656 State Street, Carlsbad, CA, United States, 92008
- Website
- tyra.bio
- Phone
- 619-728-4760
- IPO / Founded
- 2021-09-15
- Sector
- Healthcare
- Industry
- Biotechnology